Antibody-drug conjugates are big business and major deals have been struck in this area over the past year or so, with companies including Pfizer Inc., Johnson & Johnson and Merck & Co., Inc. all buying in examples of this technology.
Key Takeaways
- A handful of antibody-drug conjugates are in Phase II trials, with several readouts coming in the next couple of years.
But one group has thought better of a similar move. On 1 July, Bristol Myers Squibb Company pulled out...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
